As filed with the Securities and Exchange Commission on October 2, 1997 
Registration No. 333-        

                 SECURITIES AND EXCHANGE COMMISSION
                     Washington, D.C.  20549
                 _________________________________

                             FORM S-8
                      REGISTRATION STATEMENT
                  UNDER THE SECURITIES ACT OF 1933

                   BIOJECT MEDICAL TECHNOLOGIES INC.
           (Exact name of Registrant as specified in its charter)

                             Oregon
                  (State or other jurisdiction
                   of incorporation or organization)

    93-1099680                          7620 SW Bridgeport Road
(I.R.S. Employer                        Portland, Oregon  97224
Identification No.)                     (503) 639-7221
                              (Address of principal executive offices)

              Bioject Inc. 401(k) Retirement Benefit Plan
                       (Full title of the plan)

                           Peggy J. Miller
                        Chief Financial Officer
                        7620 SW Bridgeport Road
                        Portland, Oregon  97224
               (Name and address of agent for service)

                           (503) 639-7221
     (Telephone number, including area code, of agent for service)

Title of Securities  Amount to be Proposed Maximum Proposed      Amount of 
to be Registered     Registered   Offering Price   Maximum       Registration 
                                   Per Share(1)    Aggregate       Fee(1)
                                                   Offering Price

Common Stock,no par   100,000      $1.00           $100,000.00      $30.30
value                 shares


(1)The proposed maximum offering price per share and the registration fee 
were calculated in accordance with rule 457(c) and (h) based on the average of 
the high and low prices for shares of the registrant's Common Stock on 
September 29, 1997, as quoted by the Nasdaq National Market, which was $1.00 
per share.

In addition, pursuant to Rule 416(c) under the Securities Act of 1933, this 
registration statement also covers an indeterminate amount of interests to be 
offered or sold pursuant to the employee benefit plan described herein.

<PAGE> 1 OF

PART II.INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3. Incorporation of Documents by Reference.
Bioject Medical Technologies Inc. (the "Registrant") and the Bioject Inc. 
401(k) Retirement Benefit Plan (the "Plan") hereby incorporate by reference 
into this Registration Statement the documents listed in (a) through (d) 
below.

(a)The Registrant's latest Annual Report on Form 10-K filed pursuant 
to Section 13(a) of the Securities Exchange Act of 1934, as 
amended (the "Exchange Act"), for the Company's  fiscal year 
ended March 31, 1997.

(b)The Plan's latest annual report on Form 11-K filed pursuant to 
Section 15(d) of the Exchange Act for the Plan's fiscal year ended December 
31, 1997.

(c)All other reports filed pursuant to Section 13(a) or 15(d) of the 
Exchange Act since the filings, referred to in (a) and (b) above.

(d)The description of the Registrant's Common Stock contained in the 
Registrant's registration statement under Section 12 of the Exchange Act, 
dated January 29, 1987, and any amendment or report updating such description, 
including without limitation, Amendment No. 1 thereto dated October 5, 1987, 
Amendment No. 2 thereto dated October 26, 1987, Amendment No. 3 thereto dated 
December 23, 1987, Amendment No. 4 thereto dated January 27, 1988 and 
Amendment No. 5 thereto dated February 9, 1988, the Company's Current Reports 
on Form 8-K dated December 17, 1992, November 29, 1995 and December 14, 1995. 

All documents filed by the Registrant pursuant to Section 13(a), 14, or 15(d) 
of the Exchange Act after the date hereof and prior to the filing of a post-
effective amendment which indicates that all securities offered have been sold 
or which deregisters all securities then remaining unsold shall be deemed to 
be incorporated by reference herein and to be part hereof from the date of 
filing of such documents.

Item 4.Description of Securities
Not applicable.

Item 5.Interests of Named Experts and Counsel.
None.

Item 6.Indemnification of Directors and Officers.
Generally, Sections 60.387 through 60.414 of the Oregon Business 
Corporation Act (the "Act") authorize a court to award, or a corporation's 
board of directors to grant, indemnification to directors and officers in 
circumstances where the officer or director acted in good faith, in a manner 
that the director or officer reasonably believed to be in (or at least not 
opposed to) the best interests of the corporation and, if in a criminal 
proceeding, if the director or officer had no reasonable cause to believe his 
conduct was unlawful.  Article IX of the Registrant's Bylaws provides for 
indemnification to the greatest extent permitted by the Oregon Act.  

Section 60.047 of the Oregon Act authorizes a corporation to limit a 
director's liability to the corporation or its shareholders for monetary 
damages resulting from conduct as a director, except in certain circumstances 
involving breach of the director's duty of loyalty to the corporation or its 
shareholders, intentional misconduct or knowing violation of the law, self 
dealing or approval of illegal corporate loans or distributions, or any 
transaction from which the director personally receives a benefit in money, 
property or services to which the director is not legally entitled.  
Article VII of the Company's Articles of Incorporation contains provisions 
implementing, to the fullest extent allowed, limitations on a director's 
liability to the Registrant or its shareholders.  The Registrant currently 
maintains officers' and directors' liability insurance.

<PAGE>  II-1

Item 7.Exemption from Registration Claimed.
Not applicable.
Item 8.Exhibits.

Exhibit 
Number

4.1     Bioject Inc. 401(k) Retirement Benefit Plan

5.1     Opinion of Bogle & Gates P.L.L.C.

23.1    Consent of Bogle & Gates P.L.L.C. (included in Exhibit 5.1)

23.2    Consent of Independent Public Accountants

24.1    Power of Attorney (See page II-6 of this Registration 
        Statement)

The Registrant hereby undertakes to submit the Plan and any amendment 
thereto to the Internal Revenue Service ("IRS") in a timely manner and will 
make all changes required by the IRS to qualify the Plan.

Item 9.Undertakings.
(a)The undersigned registrant hereby undertakes:

(1)To file, during any period in which offers or sales are 
being made, a post-effective amendment to this registration statement:

(i)To include any prospectus required by Section 10(a)(3) 
of the Securities Act of 1933;

(ii)To reflect in the prospectus any facts or events 
arising after the effective date of the registration statement (or the most 
recent post-effective amendment thereof) which, individually or in the 
aggregate, represent a fundamental change in the information set forth in the 
registration statement.  Notwithstanding the foregoing, any increase or 
decrease in volume of securities offered (if the total dollar value of 
securities offered would not exceed that which was registered) and any 
deviation from the low or high end of the estimated maximum offering range may 
be reflected in the form of prospectus filed with the Commission pursuant to 
Rule 424(b) if, in the aggregate, the changes in volume and price represent no 
more than 20 percent change in the maximum aggregate offering price set forth 
in the "Calculation of Registration Fee" table in the effective registration 
statement;

(iii)To include any material information with respect to 
the plan of distribution not previously disclosed in the registration 
statement or any material change to such information in the registration 
statement; rovided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not
apply if the registration statement is on Form S-3, Form S-8 or Form F-3 and
the information required to be included in a post-effective amendment by those
paragraphs is contained in periodic reports filed by the registrant pursuant 
to Section 13 or Section 15(d) of the Exchange Act that are incorporated by 
reference in this registration statement.

(2)That for the purpose of determining any liability under the 
Securities Act of 1933, each such post-effective amendment shall be deemed to 
be a new registration statement relating to the securities offered therein, 
and the offering of such securities at that time shall be deemed to be the 
initial bona fide offering thereof.

(3)To remove from registration by means of a post-effective 
amendment any of the securities being registered which remain unsold at the 
termination of the offering.

<PAGE>  II-2

(b)The undersigned registrant hereby undertakes that, for purposes of
determining any liability under the Exchange Act, each filing of the 
registrant's annual report pursuant to Section 13(a) or Section 15(d) of the 
Exchange Act, (and, where applicable, each filing of an employee benefit 
plan's annual report pursuant to section 15(d) of the Exchange Act) that is 
incorporated by reference in the registration statement shall be deemed to be 
a new registration statement relating to the securities offered therein, and 
the offering of such securities at that time shall be deemed to be the initial 
bona fide offering thereof.

(h)Insofar as indemnification for liabilities arising under the 
Securities Act of 1933 may be permitted to directors, officers and controlling 
persons of the registrant pursuant to the foregoing provisions, or otherwise, 
the registrant has been advised that in the opinion of the Securities and 
Exchange Commission such indemnification is against public policy as expressed 
in the Act and is, therefore, unenforceable.  In the event that a claim for 
indemnification against such liabilities (other than the payment by the 
registrant of expenses incurred or paid by a director, officer or controlling 
person of the registrant in the successful defense of any action, suit or 
proceeding) is asserted by such director, officer or controlling person in 
connection with the securities being registered, the registrant will, unless 
in the opinion of its counsel the matter has been settled by controlling 
precedent, submit to a court of appropriate jurisdiction the question of 
whether such indemnification by it is against public policy as expressed in 
the Act and will be governed by the final adjudication of such issue.

<PAGE>  II-3

                                  SIGNATURES

The Plan.  Pursuant to the requirements of the Securities Act of 1933, 
the Plan Administrator has duly caused this Registration Statement to be 
signed on its behalf by the undersigned, thereunto duly authorized, in the 
city of Portland, Oregon on this 2nd day of October, 1997.

BIOJECT MEDICAL TECHNOLOGIES INC., Plan 
Administrator of the Bioject Inc. 401(k) Retirement Benefit Plan


By:/s/ Peggy J. Miller                                                          
Peggy J. Miller
Chief Financial Officer

<PAGE>  II-4

The Registrant.  Pursuant to the requirements of the Securities Act of 1933, 
the Registrant certifies that it has reasonable grounds to believe that it 
meets all of the requirements for filing on Form S-8 and has duly caused this 
Registration Statement to be signed on its behalf by the undersigned, 
thereunto duly authorized, in the city of Portland, Oregon on this 2nd day 
of October, 1997.

BIOJECT MEDICAL TECHNOLOGIES INC.


By:/s/ Peggy J. Miller                                                    
Peggy J. Miller
Chief Financial Officer

<PAGE>  II-5

                           Power of Attorney

Each person whose signature appears below constitutes and appoints James 
C. O'Shea and Peggy J. Miller, or either of them, his attorney-in-fact, with 
the power of substitution, for him in any and all capacities, to sign any 
amendments to this Registration Statement, and to file the same, with exhibits 
thereto and other documents in connection therewith, with the Securities and 
Exchange Commission, hereby ratifying and confirming all that said attorneys-
in-fact, or their substitute or substitutes, may do or cause to be done by 
virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this 
registration statement has been signed by the following persons in the 
capacities and on the date indicated.  

Signature                Title                       Date

/s/James C. O'Shea       Chairman of the Board,      October 1, 1997
James C. O'Shea          Chief Executive Officer  
                         and President (Principal 
                         Executive Officer)

/s/Peggy J. Miller       Vice President, Chief       October 1, 1997
Peggy J. Miller          Financial Officer and 
                         Secretary/Treasurer 
                        (Principal Accounting and 
                         Financial Officer)

/s/William A. Gouveia      Director                  September 30, 1997
William A. Gouveia

/s/John Ruedy, M.D.        Director                  October 1, 1997
John Ruedy, M.D.

                                             
Grace Keeney Fey           Director

/s/Eric T. Herfindal       Director                  September 30, 1997
Eric T. Herfindal

/s/Richard J. Plestina     Director                  September 30, 1997 
Richard J. Plestina

/s/David H. de Weese       Director                  September 30, 1997
David H. de Weese

<PAGE>  II-6


Exhibit 
Number                   Exhibit                                

4.1       Bioject Inc. 401(k) Retirement Benefit Plan

5.1       Opinion of Bogle & Gates P.L.L.C.

23.1      Consent of Bogle & Gates P.L.L.C. (included in 
          Exhibit 5.1)

23.2      Consent of Independent Public Accountants

24.1      Power of Attorney (See page II-6 of this 
          Registration Statement)

<PAGE>  II-7



                                                               Exhibit 5.1

               OPINION OF BOGLE & GATES P.L.L.C.

            
October 2, 1997

Bioject Medical Technologies Inc.
7620 S.W. Bridgeport Road
Portland, OR  97224

Gentlemen and Ladies:

We are delivering this opinion in connection with the Registration 
Statement on Form S-8 (the "Registration Statement") of Bioject 
Medical Technologies Inc. (the "Company") to be filed with the 
Securities and Exchange Commission under the Securities Act of 1933, 
as amended (the "Securities Act"), with respect to an aggregate of 
100,000 shares, without par value, of common stock of the Company 
(the "Shares") to issued by the Company as plan administrator of the 
Bioject, Inc. 401(k) Retirement Benefit Plan (the "Plan").

We have examined and are familiar with originals or copies, certified 
or otherwise identified to our satisfaction, of such documents, 
corporate records and other instruments relating to the incorporation 
of the Company and to the authorization and issuance of the Shares, 
and have made such investigations of law, as we have deemed necessary 
and advisable.

Based upon the foregoing and having due regard for such legal 
questions as we have deemed relevant, we are of the opinion that the 
Shares have been duly authorized, and, when issued, 
constitute or will constitute duly authorized, legally issued, fully 
paid and nonassessable shares of common stock of the Company.

We hereby consent to the filing of this opinion as an exhibit to the 
Registration Statement referred to above, and to the reference to our firm
in the Prospectus constituting a part of the Registration Statement.

Very truly yours,


/s/ Bogle & Gates P.L.L.C.
 
                                                                            
                                                               Exhibit 23.2

        CONSENT OF INDEPENDENT PUBLIC ACCOUNTANTS   
       
As independent public accountants, we hereby consent to the incorporation by
reference in this Form S-8 Registration Statement of our report dated
May 2, 1997 included in the Bioject Medical Technologies, Inc. Annual Report
on Form 10-K for the fiscal year ended March 31, 1997 and to all references to
our Firm included in this Registration Statement.

   
           /S/ ARTHUR ANDERSEN LLP   
   
Portland, Oregon   
September 29, 1997
[{"type": "S-8", "sequence": "1", "secsgml_size_bytes": 16457}]
{"company-data": {"conformed-name": "BIOJECT MEDICAL TECHNOLOGIES INC", "cik": "0000810084", "assigned-sic": "3841", "irs-number": "931099680", "state-of-incorporation": "OR", "fiscal-year-end": "0331"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-37017", "film-number": "97689881"}, "business-address": {"street1": "7620 S W BRIDGEPORT RD", "city": "PORTLAND", "state": "OR", "zip": "97224", "phone": "5036397221"}, "former-company": {"former-conformed-name": "BIOJECT MEDICAL SYSTEMS LTD", "date-changed": "19920703"}}
As filed with the Securities and Exchange Commission on October 2, 1997 
Registration No. 333-        

                 SECURITIES AND EXCHANGE COMMISSION
                     Washington, D.C.  20549
                 _________________________________

                             FORM S-8
                      REGISTRATION STATEMENT
                  UNDER THE SECURITIES ACT OF 1933

                   BIOJECT MEDICAL TECHNOLOGIES INC.
           (Exact name of Registrant as specified in its charter)

                             Oregon
                  (State or other jurisdiction
                   of incorporation or organization)

    93-1099680                          7620 SW Bridgeport Road
(I.R.S. Employer                        Portland, Oregon  97224
Identification No.)                     (503) 639-7221
                              (Address of principal executive offices)

              Bioject Inc. 401(k) Retirement Benefit Plan
                       (Full title of the plan)

                           Peggy J. Miller
                        Chief Financial Officer
                        7620 SW Bridgeport Road
                        Portland, Oregon  97224
               (Name and address of agent for service)

                           (503) 639-7221
     (Telephone number, including area code, of agent for service)

Title of Securities  Amount to be Proposed Maximum Proposed      Amount of 
to be Registered     Registered   Offering Price   Maximum       Registration 
                                   Per Share(1)    Aggregate       Fee(1)
                                                   Offering Price

Common Stock,no par   100,000      $1.00           $100,000.00      $30.30
value                 shares

(1)The proposed maximum offering price per share and the registration fee 
were calculated in accordance with rule 457(c) and (h) based on the average of 
the high and low prices for shares of the registrant's Common Stock on 
September 29, 1997, as quoted by the Nasdaq National Market, which was $1.00 
per share.

In addition, pursuant to Rule 416(c) under the Securities Act of 1933, this 
registration statement also covers an indeterminate amount of interests to be 
offered or sold pursuant to the employee benefit plan described herein.
1 OF

PART II.INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3. Incorporation of Documents by Reference.
Bioject Medical Technologies Inc. (the "Registrant") and the Bioject Inc. 
401(k) Retirement Benefit Plan (the "Plan") hereby incorporate by reference 
into this Registration Statement the documents listed in (a) through (d) 
below.

(a)The Registrant's latest Annual Report on Form 10-K filed pursuant 
to Section 13(a) of the Securities Exchange Act of 1934, as 
amended (the "Exchange Act"), for the Company's  fiscal year 
ended March 31, 1997.

(b)The Plan's latest annual report on Form 11-K filed pursuant to 
Section 15(d) of the Exchange Act for the Plan's fiscal year ended December 
31, 1997.

(c)All other reports filed pursuant to Section 13(a) or 15(d) of the 
Exchange Act since the filings, referred to in (a) and (b) above.

(d)The description of the Registrant's Common Stock contained in the 
Registrant's registration statement under Section 12 of the Exchange Act, 
dated January 29, 1987, and any amendment or report updating such description, 
including without limitation, Amendment No. 1 thereto dated October 5, 1987, 
Amendment No. 2 thereto dated October 26, 1987, Amendment No. 3 thereto dated 
December 23, 1987, Amendment No. 4 thereto dated January 27, 1988 and 
Amendment No. 5 thereto dated February 9, 1988, the Company's Current Reports 
on Form 8-K dated December 17, 1992, November 29, 1995 and December 14, 1995. 

All documents filed by the Registrant pursuant to Section 13(a), 14, or 15(d) 
of the Exchange Act after the date hereof and prior to the filing of a post-
effective amendment which indicates that all securities offered have been sold 
or which deregisters all securities then remaining unsold shall be deemed to 
be incorporated by reference herein and to be part hereof from the date of 
filing of such documents.

Item 4.Description of Securities
Not applicable.

Item 5.Interests of Named Experts and Counsel.
None.

Item 6.Indemnification of Directors and Officers.
Generally, Sections 60.387 through 60.414 of the Oregon Business 
Corporation Act (the "Act") authorize a court to award, or a corporation's 
board of directors to grant, indemnification to directors and officers in 
circumstances where the officer or director acted in good faith, in a manner 
that the director or officer reasonably believed to be in (or at least not 
opposed to) the best interests of the corporation and, if in a criminal 
proceeding, if the director or officer had no reasonable cause to believe his 
conduct was unlawful.  Article IX of the Registrant's Bylaws provides for 
indemnification to the greatest extent permitted by the Oregon Act.  

Section 60.047 of the Oregon Act authorizes a corporation to limit a 
director's liability to the corporation or its shareholders for monetary 
damages resulting from conduct as a director, except in certain circumstances 
involving breach of the director's duty of loyalty to the corporation or its 
shareholders, intentional misconduct or knowing violation of the law, self 
dealing or approval of illegal corporate loans or distributions, or any 
transaction from which the director personally receives a benefit in money, 
property or services to which the director is not legally entitled.  
Article VII of the Company's Articles of Incorporation contains provisions 
implementing, to the fullest extent allowed, limitations on a director's 
liability to the Registrant or its shareholders.  The Registrant currently 
maintains officers' and directors' liability insurance.
II-1

Item 7.Exemption from Registration Claimed.
Not applicable.
Item 8.Exhibits.

Exhibit 
Number

4.1     Bioject Inc. 401(k) Retirement Benefit Plan

5.1     Opinion of Bogle & Gates P.L.L.C.

23.1    Consent of Bogle & Gates P.L.L.C. (included in Exhibit 5.1)

23.2    Consent of Independent Public Accountants

24.1    Power of Attorney (See page II-6 of this Registration 
        Statement)

The Registrant hereby undertakes to submit the Plan and any amendment 
thereto to the Internal Revenue Service ("IRS") in a timely manner and will 
make all changes required by the IRS to qualify the Plan.

Item 9.Undertakings.
(a)The undersigned registrant hereby undertakes:

(1)To file, during any period in which offers or sales are 
being made, a post-effective amendment to this registration statement:

(i)To include any prospectus required by Section 10(a)(3) 
of the Securities Act of 1933;

(ii)To reflect in the prospectus any facts or events 
arising after the effective date of the registration statement (or the most 
recent post-effective amendment thereof) which, individually or in the 
aggregate, represent a fundamental change in the information set forth in the 
registration statement.  Notwithstanding the foregoing, any increase or 
decrease in volume of securities offered (if the total dollar value of 
securities offered would not exceed that which was registered) and any 
deviation from the low or high end of the estimated maximum offering range may 
be reflected in the form of prospectus filed with the Commission pursuant to 
Rule 424(b) if, in the aggregate, the changes in volume and price represent no 
more than 20 percent change in the maximum aggregate offering price set forth 
in the "Calculation of Registration Fee" table in the effective registration 
statement;

(iii)To include any material information with respect to 
the plan of distribution not previously disclosed in the registration 
statement or any material change to such information in the registration 
statement; rovided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not
apply if the registration statement is on Form S-3, Form S-8 or Form F-3 and
the information required to be included in a post-effective amendment by those
paragraphs is contained in periodic reports filed by the registrant pursuant 
to Section 13 or Section 15(d) of the Exchange Act that are incorporated by 
reference in this registration statement.

(2)That for the purpose of determining any liability under the 
Securities Act of 1933, each such post-effective amendment shall be deemed to 
be a new registration statement relating to the securities offered therein, 
and the offering of such securities at that time shall be deemed to be the 
initial bona fide offering thereof.

(3)To remove from registration by means of a post-effective 
amendment any of the securities being registered which remain unsold at the 
termination of the offering.
II-2

(b)The undersigned registrant hereby undertakes that, for purposes of
determining any liability under the Exchange Act, each filing of the 
registrant's annual report pursuant to Section 13(a) or Section 15(d) of the 
Exchange Act, (and, where applicable, each filing of an employee benefit 
plan's annual report pursuant to section 15(d) of the Exchange Act) that is 
incorporated by reference in the registration statement shall be deemed to be 
a new registration statement relating to the securities offered therein, and 
the offering of such securities at that time shall be deemed to be the initial 
bona fide offering thereof.

(h)Insofar as indemnification for liabilities arising under the 
Securities Act of 1933 may be permitted to directors, officers and controlling 
persons of the registrant pursuant to the foregoing provisions, or otherwise, 
the registrant has been advised that in the opinion of the Securities and 
Exchange Commission such indemnification is against public policy as expressed 
in the Act and is, therefore, unenforceable.  In the event that a claim for 
indemnification against such liabilities (other than the payment by the 
registrant of expenses incurred or paid by a director, officer or controlling 
person of the registrant in the successful defense of any action, suit or 
proceeding) is asserted by such director, officer or controlling person in 
connection with the securities being registered, the registrant will, unless 
in the opinion of its counsel the matter has been settled by controlling 
precedent, submit to a court of appropriate jurisdiction the question of 
whether such indemnification by it is against public policy as expressed in 
the Act and will be governed by the final adjudication of such issue.
II-3

                                  SIGNATURES

The Plan.  Pursuant to the requirements of the Securities Act of 1933, 
the Plan Administrator has duly caused this Registration Statement to be 
signed on its behalf by the undersigned, thereunto duly authorized, in the 
city of Portland, Oregon on this 2nd day of October, 1997.

BIOJECT MEDICAL TECHNOLOGIES INC., Plan 
Administrator of the Bioject Inc. 401(k) Retirement Benefit Plan

By:/s/ Peggy J. Miller                                                          
Peggy J. Miller
Chief Financial Officer
II-4

The Registrant.  Pursuant to the requirements of the Securities Act of 1933, 
the Registrant certifies that it has reasonable grounds to believe that it 
meets all of the requirements for filing on Form S-8 and has duly caused this 
Registration Statement to be signed on its behalf by the undersigned, 
thereunto duly authorized, in the city of Portland, Oregon on this 2nd day 
of October, 1997.

BIOJECT MEDICAL TECHNOLOGIES INC.

By:/s/ Peggy J. Miller                                                    
Peggy J. Miller
Chief Financial Officer
II-5

                           Power of Attorney

Each person whose signature appears below constitutes and appoints James 
C. O'Shea and Peggy J. Miller, or either of them, his attorney-in-fact, with 
the power of substitution, for him in any and all capacities, to sign any 
amendments to this Registration Statement, and to file the same, with exhibits 
thereto and other documents in connection therewith, with the Securities and 
Exchange Commission, hereby ratifying and confirming all that said attorneys-
in-fact, or their substitute or substitutes, may do or cause to be done by 
virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this 
registration statement has been signed by the following persons in the 
capacities and on the date indicated.  

Signature                Title                       Date

/s/James C. O'Shea       Chairman of the Board,      October 1, 1997
James C. O'Shea          Chief Executive Officer  
                         and President (Principal 
                         Executive Officer)

/s/Peggy J. Miller       Vice President, Chief       October 1, 1997
Peggy J. Miller          Financial Officer and 
                         Secretary/Treasurer 
                        (Principal Accounting and 
                         Financial Officer)

/s/William A. Gouveia      Director                  September 30, 1997
William A. Gouveia

/s/John Ruedy, M.D.        Director                  October 1, 1997
John Ruedy, M.D.

                                             
Grace Keeney Fey           Director

/s/Eric T. Herfindal       Director                  September 30, 1997
Eric T. Herfindal

/s/Richard J. Plestina     Director                  September 30, 1997 
Richard J. Plestina

/s/David H. de Weese       Director                  September 30, 1997
David H. de Weese
II-6

Exhibit 
Number                   Exhibit                                

4.1       Bioject Inc. 401(k) Retirement Benefit Plan

5.1       Opinion of Bogle & Gates P.L.L.C.

23.1      Consent of Bogle & Gates P.L.L.C. (included in 
          Exhibit 5.1)

23.2      Consent of Independent Public Accountants

24.1      Power of Attorney (See page II-6 of this 
          Registration Statement)
II-7

                                                               Exhibit 5.1

               OPINION OF BOGLE & GATES P.L.L.C.

            
October 2, 1997

Bioject Medical Technologies Inc.
7620 S.W. Bridgeport Road
Portland, OR  97224

Gentlemen and Ladies:

We are delivering this opinion in connection with the Registration 
Statement on Form S-8 (the "Registration Statement") of Bioject 
Medical Technologies Inc. (the "Company") to be filed with the 
Securities and Exchange Commission under the Securities Act of 1933, 
as amended (the "Securities Act"), with respect to an aggregate of 
100,000 shares, without par value, of common stock of the Company 
(the "Shares") to issued by the Company as plan administrator of the 
Bioject, Inc. 401(k) Retirement Benefit Plan (the "Plan").

We have examined and are familiar with originals or copies, certified 
or otherwise identified to our satisfaction, of such documents, 
corporate records and other instruments relating to the incorporation 
of the Company and to the authorization and issuance of the Shares, 
and have made such investigations of law, as we have deemed necessary 
and advisable.

Based upon the foregoing and having due regard for such legal 
questions as we have deemed relevant, we are of the opinion that the 
Shares have been duly authorized, and, when issued, 
constitute or will constitute duly authorized, legally issued, fully 
paid and nonassessable shares of common stock of the Company.

We hereby consent to the filing of this opinion as an exhibit to the 
Registration Statement referred to above, and to the reference to our firm
in the Prospectus constituting a part of the Registration Statement.

Very truly yours,

/s/ Bogle & Gates P.L.L.C.
 
                                                                            
                                                               Exhibit 23.2

        CONSENT OF INDEPENDENT PUBLIC ACCOUNTANTS   
       
As independent public accountants, we hereby consent to the incorporation by
reference in this Form S-8 Registration Statement of our report dated
May 2, 1997 included in the Bioject Medical Technologies, Inc. Annual Report
on Form 10-K for the fiscal year ended March 31, 1997 and to all references to
our Firm included in this Registration Statement.

   
           /S/ ARTHUR ANDERSEN LLP   
   
Portland, Oregon   
September 29, 1997